NovoCure (NVCR) Notes Payables (2024 - 2025)
NovoCure recorded quarterly Notes Payables of $560.6 million in Q3 2025, little changed quarter-over-quarter from $559.8 million in Q2 2025, and up 0.59% year-over-year from $557.3 million in Q3 2024.
NovoCure's Notes Payables history runs 2 years deep, the most recent figure standing at $560.6 million for Q3 2025.
- In Q3 2025, Notes Payables rose 0.59% year-over-year to $560.6 million; the TTM figure through Sep 2025 stood at $560.6 million (up 0.59% YoY), while the FY2024 annual figure was $558.2 million, changed N/A from the prior year.
- Notes Payables came in at $560.6 million for Q3 2025 at NovoCure, roughly flat from $559.8 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $560.6 million in Q3 2025 to a low of $557.3 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 560.62 Mn |
| Jun 30, 2025 | 559.79 Mn |
| Mar 31, 2025 | 558.97 Mn |
| Dec 31, 2024 | 558.16 Mn |
| Sep 30, 2024 | 557.33 Mn |